

Richter and Allergan expanded their distribution and supply agreement for Levosert™ to Latin America

Budapest, Hungary – 12 February 2019 – Gedeon Richter Plc. (hereinafter: “Richter”) today announced that it has entered into a distribution and supply agreement with a wholly owned subsidiary of Allergan plc (hereinafter: “Allergan”) to commercialize its levonorgestrel releasing Intrauterine System (IUS) in Latin American countries. The product is already marketed by Richter under the trademark of Levosert™ since 2011 in most of Europe through agreements established with Allergan.

Sales related royalties and milestone payments will become payable to Allergan subsequent to the launch of the product.

About Gedeon Richter

Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China and in Latin America. Having reached a market capitalisation of EUR 4.1 billion (USD 4.9 billion) by the end of 2017, Richter's consolidated sales were approximately EUR 1.4 billion (USD 1.6 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's healthcare field worldwide. Richter is also active in biosimilar product development.

For more information:

Investors:

Katalin Ördög: +36 1 431 5680

Media:

Zsuzsa Beke: +36 1 431 4888